Source comparison
How DAC Technology Affects IGF-1 Response Versus Direct GH Measurement
Growth hormone stimulates IGF-1 (insulin-like growth factor 1) production primarily in the liver, and IGF-1 mediates many of GH's anabolic effects. CJC-1295 with DAC elevates both GH and IGF-1, but the kinetics differ meaningfully. GH peaks within hours of CJC
This comparison does not assign a generated winner or score.
- Growth hormone stimulates IGF-1 (insulin-like growth factor 1) production primarily in the liver, and IGF-1 mediates many of GH's anabolic effects. CJC-1295 with DAC elevates both GH and IGF-1, but the kinetics differ meaningfully. GH peaks within hours of CJC-1295 administration, while IGF-1 rises more gradually and remains elevated longer. IGF-1 has its own half-life of approximately 12–15 hours, independent of GH. Studies measuring only GH may miss the downstream anabolic signal; studies measuring only IGF-1 may underestimate peak GH exposure.
- Research from the Journal of Clinical Endocrinology & Metabolism demonstrated that CJC-1295 with DAC increased mean IGF-1 levels by 1.5–3 times baseline, sustained for over one week following a single injection. This makes IGF-1 a more stable biomarker for long-term studies than GH itself, which fluctuates even with DAC due to residual pulsatility from endogenous GHRH. If your protocol tracks body composition changes over 8–12 weeks, measuring IGF-1 every 7–10 days provides a clearer picture of sustained anabolic signaling than daily GH sampling.
- One caveat: IGF-1 elevation doesn't scale linearly with GH dose. At higher CJC-1295 doses, GH continues rising, but IGF-1 response plateaus due to hepatic receptor saturation and negative feedback from IGFBP-3 (IGF binding protein 3). This ceiling effect matters for dose-finding studies. Pushing CJC-1295 beyond 60 mcg/kg doesn't produce proportional IGF-1 gains and increases the risk of side effects like joint stiffness or insulin resistance. Protocols at Real Peptides account for this by capping research doses at levels where IGF-1 response remains robust without hitting saturation.